CELL LINES
Contributor Information
- Institute Erasmus University Medical Center (Erasmus MC)
Tool Details
- Tool name: ZR-75-1 estrogen independent breast cancer cell line panel (2)
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: ZR-75-1
- Organism: Human
- Tissue: Breast
- Cancer type: Mammary ductal carcinoma; Estrogen independent
- Disease: Cancer
- Model: Cancer Model
- Conditional: No
- Description: Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied different genetic screens to identify the main genes conferring estrogen independence. Out of 15 candidate BCAR genes, several including BCAR1, BCAR3, AKT1, AKT2, BCAR4, GRB7, EGFR, HRAS, PDGFRA, PDGFRB and RAF1 were shown to directly underlie estrogen independence by transfection into the ZR-75-1 breast cancer cell line resulting in a panel of 16 cell lines (Cat No 154621-154635, 154642) These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity. These cell lines are resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells. As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.
- Research area: Cancer; Drug Discovery & Development
- Production details: Full length cDNA of the relevant gene was introduced in the estrogen-dependent ZR-75-1 cell line by transfection with lipofectamine
- For Research Use Only
Target Details
- Target: BCAR1, BCAR3, AKT1, AKT2, BCAR4, GRB7, EGFR, HRAS, PDGFRA, PDGFRB, RAF1
Application Details
- Application notes: These cell lines are resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells. As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.
Handling
- Format: Frozen
- Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
- Shipping conditions: Dry ice
Documentation
- Available on request
Related Tools
References
- • Godinho et al. 2011. J Cell Physiol. 226(7):1741-9. PMID: 21506106.
- • van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.
- • van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.
- • Meijer et al. 2006. Mol Cancer Res. 4(6):379-86. PMID: 16778085.
- • Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.
- • van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.
- • van Agthoven et al. 1992. Cancer Res. 52(18):5082-8. PMID: 1516065.
.svg)
Unit size: 
.svg)
.svg)
